AgingResearch.NewsJoin free

Theranexus

CompanyFranceFounded 2013

Wikidata

Theranexus develops one asset, in phase 1 (THN 201 in Alzheimer's disease). Mostly small molecule acting on ACHE and GJA1; based in France, founded in 2013.

1
Asset
Furthest stage
Phase 1
1
Trial
0
Signals

Pipeline

1

  • THN 201

    Acetylcholinesterase inhibitor combined with a connexin modulator to enhance cognitive function.

    Phase 1, Small molecule, ACHE, GJA1, Alzheimer's disease, cognitive impairment

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials1
  • Similar companies6

Intelligence